Healthcare Costs
-
Another bite at the apple
Read more: Another bite at the appleIt used to be that pharmaceutical manufacturers had to worry (mostly) about federal health policy. Every few years manage through a big piece of legislation from Congress and then the regulation on Medicare, Medicaid, the Affordable Care Act and any regulation that came out of the legislation. But over the past few years, the drug…
-
A Walk on the Wild Side: Parallels between University Sports and 340B
Read more: A Walk on the Wild Side: Parallels between University Sports and 340BOne of my resolutions for this year is to get outside for a good walk every day. Get some air, get some steps, listen to a podcast. A break from work. Unless the podcast on money in university sports gets the thoughts spiraling to work parallels. Yesterday I was listening to the New York Time’s…
-
Caught my eye — 1/5/24
Read more: Caught my eye — 1/5/24Orange you glad? Florida got approval from the Food and Drug Administration to import drugs from Canada. Ho-hum. The “how” still has to be figured out and approved and that isn’t easy. Canada has about the population of California. It doesn’t want to supply the United States with drugs. It’s one of those ideas that…
-
Caught my eye, Healthcare Costs, Inflation Reduction Act, Medicare Negotiation, Pharmacy Benefit ManagersCaught my eye — 12/15/23
Read more: Caught my eye — 12/15/23Driving home (the message.) Yesterday President Biden drove up to the National Institutes of Health and gave a speech about drug prices. My main issue with it is the traffic caused by shutting down the beltway and all the roads around my neighborhood. Okay and I think that a lot of the inflation penalties for…
-
Catastrophic Communications
Read more: Catastrophic CommunicationsYesterday, the Kaiser Family Foundation released survey results that showed that only 25% of adults over 65 knew about the Medicare prescription drug benefit (Part D) out-of-pocket cap starting in January 2024. Coincidentally, I also spent a chunk of yesterday explaining the $0 patient cost-sharing in catastrophic to two different groups yesterday. Both of whom…
-
Caught my eye — 12/8/23
Read more: Caught my eye — 12/8/23Marching right past. Senator Bernie Sanders held up the head of the NIH hearings because he wanted to make sure march-in rights were part of the policy conversations on drug pricing. I can’t decide if march-in rights are like your 1st grade teacher asking for part of your salary because she was part of your…
-
Caught my eye — 12/1/23
Read more: Caught my eye — 12/1/23Patient no more. A few weeks ago I wrote about how thanks to the HIV Hepatitis Policy Institute, the Diabetes Leadership Council and the Diabetes Patient Advocacy Coalition and their suit against the Department of Health and Human Services, accumulator programs were dealt a blow. They can only be used if it is for a branded…
-
Caught my eye — 10/27/23
Read more: Caught my eye — 10/27/23Caught my ear? This story on NPR about drug shortages and how one woman is trying to plug the holes was fantastic. Two takeaways – (1) never underestimate a mother whose kid needs help and (2) figuring out drug shortages should be more systematic and not a game of “whack a mole.” Nothing but net.…
Latest news
- Caught my eye — 03/28/25
- Caught my eye — 3/21/25
- Caught my eye — 3/14/25
- Caught my eye — 03/07/25
- Caught my eye — 2/28/25
Categories
- 340B (33)
- Affordable Care Act (4)
- Alzheimer's (5)
- Biosimilars (20)
- Caught my eye (61)
- Cell and Gene (1)
- Chevron Deference (2)
- CMMI (10)
- Copay Accumulators (6)
- COVID (2)
- Drug Prices (30)
- Drug shortages (8)
- DTC (2)
- Employers (7)
- Generics (5)
- Health Equity (3)
- Healthcare Costs (28)
- ICER (9)
- Importation (2)
- Inflation Reduction Act (45)
- Insulin (4)
- IP (3)
- Long term care (1)
- Medicaid (6)
- Medicare Advantage (15)
- Medicare Negotiation (48)
- Medicare Part D (44)
- Medicare Transaction Facilitator (2)
- Medicare Transaction Facilitator (7)
- Obesity (20)
- On the Horizon (1)
- Orphan Drugs (3)
- Pharmacy Benefit Managers (28)
- Reference Pricing (5)
- State-based Reform (14)
- Supply Chain (1)
- Uncategorized (4)
- Utilization Management (1)
- Vaccines (4)
- Value (12)